Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Targeting the Th17 pathway in psoriasis.

Elloso MM, Gomez-Angelats M, Fourie AM.

J Leukoc Biol. 2012 Dec;92(6):1187-97. doi: 10.1189/jlb.0212101. Epub 2012 Sep 7. Review.

2.

Etanercept downregulates the Th17 pathway and decreases the IL-17+/IL-10+ cell ratio in patients with psoriasis vulgaris.

Antiga E, Volpi W, Cardilicchia E, Maggi L, Filì L, Manuelli C, Parronchi P, Fabbri P, Caproni M.

J Clin Immunol. 2012 Dec;32(6):1221-32. doi: 10.1007/s10875-012-9716-x. Epub 2012 Jun 15.

PMID:
22699761
3.

Th1, Th2, Th17 and regulatory T cell pattern in psoriatic patients: modulation of cytokines and gene targets induced by etanercept treatment and correlation with clinical response.

Quaglino P, Bergallo M, Ponti R, Barberio E, Cicchelli S, Buffa E, Comessatti A, Costa C, Terlizzi ME, Astegiano S, Novelli M, Cavallo R, Bernengo MG.

Dermatology. 2011;223(1):57-67. doi: 10.1159/000330330. Epub 2011 Aug 25.

PMID:
21865674
4.

Cytokine network in psoriasis revisited.

Michalak-Stoma A, Pietrzak A, Szepietowski JC, Zalewska-Janowska A, Paszkowski T, Chodorowska G.

Eur Cytokine Netw. 2011 Dec;22(4):160-8. doi: 10.1684/ecn.2011.0294. Review.

PMID:
22236965
5.

Interleukin 17A: toward a new understanding of psoriasis pathogenesis.

Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S.

J Am Acad Dermatol. 2014 Jul;71(1):141-50. doi: 10.1016/j.jaad.2013.12.036. Epub 2014 Mar 18. Review.

PMID:
24655820
6.

The roles of cells and cytokines in the pathogenesis of psoriasis.

Coimbra S, Figueiredo A, Castro E, Rocha-Pereira P, Santos-Silva A.

Int J Dermatol. 2012 Apr;51(4):389-95; quiz 395-8. doi: 10.1111/j.1365-4632.2011.05154.x. Review.

PMID:
22435425
7.

Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis.

Mudigonda P, Mudigonda T, Feneran AN, Alamdari HS, Sandoval L, Feldman SR.

Dermatol Online J. 2012 Oct 15;18(10):1. Review.

8.

Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies.

Maddur MS, Miossec P, Kaveri SV, Bayry J.

Am J Pathol. 2012 Jul;181(1):8-18. doi: 10.1016/j.ajpath.2012.03.044. Epub 2012 May 26. Review.

PMID:
22640807
9.

Th17 cells and IL-17 a--focus on immunopathogenesis and immunotherapeutics.

van den Berg WB, McInnes IB.

Semin Arthritis Rheum. 2013 Oct;43(2):158-70. doi: 10.1016/j.semarthrit.2013.04.006. Review.

PMID:
24157091
10.

Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis.

Singh TP, Schön MP, Wallbrecht K, Gruber-Wackernagel A, Wang XJ, Wolf P.

PLoS One. 2013;8(1):e51752. doi: 10.1371/journal.pone.0051752. Epub 2013 Jan 15.

11.

Interleukin-17 in inflammatory skin disorders.

van Beelen AJ, Teunissen MB, Kapsenberg ML, de Jong EC.

Curr Opin Allergy Clin Immunol. 2007 Oct;7(5):374-81. Review.

PMID:
17873575
12.

A pathogenetic approach to autoimmune skin disease therapy: psoriasis and biological drugs, unresolved issues, and future directions.

Ayroldi E, Bastianelli A, Cannarile L, Petrillo MG, Delfino DV, Fierabracci A.

Curr Pharm Des. 2011;17(29):3176-90. Review.

PMID:
21864268
13.

The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases.

Toussirot E.

Inflamm Allergy Drug Targets. 2012 Apr;11(2):159-68. Review.

PMID:
22280236
14.

Critical role of the interleukin-23/T-helper 17 cell axis in the pathogenesis of psoriasis.

Nakajima K.

J Dermatol. 2012 Mar;39(3):219-24. doi: 10.1111/j.1346-8138.2011.01458.x. Review.

PMID:
22352845
15.

Interleukin-17 in inflammatory myopathies.

Tournadre A, Miossec P.

Curr Rheumatol Rep. 2012 Jun;14(3):252-6. doi: 10.1007/s11926-012-0242-x. Review.

PMID:
22350607
16.

Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis.

Mease PJ.

Curr Opin Rheumatol. 2015 Mar;27(2):127-33. doi: 10.1097/BOR.0000000000000147. Review.

PMID:
25599143
17.

Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines.

Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A.

Curr Rheumatol Rep. 2007 Dec;9(6):461-7. Review.

18.

Impaired expression of Tim-3 on Th17 and Th1 cells in psoriasis.

Kanai Y, Satoh T, Igawa K, Yokozeki H.

Acta Derm Venereol. 2012 Jul;92(4):367-71. doi: 10.2340/00015555-1285.

19.

Th17 response and its regulation in inflammatory upper airway diseases.

Liu Y, Zeng M, Liu Z.

Clin Exp Allergy. 2015 Mar;45(3):602-12. doi: 10.1111/cea.12378. Review.

PMID:
25048954
20.

The IL-17 pathway as a major therapeutic target in autoimmune diseases.

Hu Y, Shen F, Crellin NK, Ouyang W.

Ann N Y Acad Sci. 2011 Jan;1217:60-76. doi: 10.1111/j.1749-6632.2010.05825.x. Epub 2010 Dec 13. Review.

PMID:
21155836
Items per page

Supplemental Content

Write to the Help Desk